Drug intelligence / Profile preview

ILM-22

Development stage: Unknown
Lead developer: Illimis Therapeutics
Modality: Small Molecules

Overview

ILM-22 is a drug candidate classified as a TNF-alpha inhibitor. It was initially developed by Illimis Therapeutics. The mechanism of action involves inhibition of tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation and implicated in various autoimmune and inflammatory diseases. As of the latest available information, ILM-22 remains at the discovery stage, with no advanced clinical development or approved indications reported[1].

Other names: ILM22ILM-22ILM 22

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on ILM-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILM-22.

Explore the full profile